Special Issue "Therapeutics Agents for Neural Repair"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 30 May 2019

Special Issue Editor

Guest Editor
Dr. Nuno A. Silva

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
Website | E-Mail
Interests: spinal cord injury; regenerative medicine

Special Issue Information

Dear Colleagues,

An insult on the Central Nervous System (CNS) usually leads to permanent and irreversible pathological conditions. Events, such as stroke, trauma or neurodegenerative diseases, have a strong impact on the physiological, psychological and social behavior of patients. For these reasons, it is urgent to develop therapeutic strategies that can specifically target these problems. Typically, the pathophysiology of these conditions entail several molecular and cellular events and, given its multifaceted nature, many conceptually different paths are under investigation to promote neural repair. This Special Issue is dedicated to “Therapeutics Agents for Neural Repair” and it is mainly focused on the use of pharmaceutical agents, administrated alone or in combination with other therapeutic approaches.

I sincerely hope that you will be able to contribute a research manuscript or review article dealing with your research in this area of investigation. The proposed topics include, but are not limited to:

  • Pathologies of the CNS (Parkinson, Alzheimer, Huntington, multiple sclerosis, depression, autism, Machado-Joseph, amyotrophic lateral sclerosis, stroke, traumatic brain injury, spinal cord injury).
  • Therapeutic Approaches (molecular therapy, cell therapy, gene therapy, deep brain/epidural stimulation, tissue engineering).
  • Personalized medicine
  • Biomarkers of disease
  • In vitro/ex vivo studies
  • In vivo preclinical studies
  • Clinical studies

I look forward to your participation.

Dr. Nuno A. Silva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Neural Repair
  • Neuroprotection
  • Neuroregeration
  • Trauma
  • Neurodegenerative Disease
  • Therapeutic Agents
  • Biomarkers

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Pharmaceuticals 2019, 12(1), 41; https://doi.org/10.3390/ph12010041
Received: 15 February 2019 / Revised: 13 March 2019 / Accepted: 15 March 2019 / Published: 19 March 2019
PDF Full-text (9116 KB) | HTML Full-text | XML Full-text
Abstract
Alzheimer’s disease (AD) is a growing global health concern with a massive impact on affected individuals and society. Despite the considerable advances achieved in the understanding of AD pathogenesis, researchers have not been successful in fully identifying the mechanisms involved in disease progression. [...] Read more.
Alzheimer’s disease (AD) is a growing global health concern with a massive impact on affected individuals and society. Despite the considerable advances achieved in the understanding of AD pathogenesis, researchers have not been successful in fully identifying the mechanisms involved in disease progression. The amyloid hypothesis, currently the prevalent theory for AD, defends the deposition of β-amyloid protein (Aβ) aggregates as the trigger of a series of events leading to neuronal dysfunction and dementia. Hence, several research and development (R&D) programs have been led by the pharmaceutical industry in an effort to discover effective and safety anti-amyloid agents as disease modifying agents for AD. Among 19 drug candidates identified in the AD pipeline, nine have their mechanism of action centered in the activity of β or γ-secretase proteases, covering almost 50% of the identified agents. These drug candidates must fulfill the general rigid prerequisites for a drug aimed for central nervous system (CNS) penetration and selectivity toward different aspartyl proteases. This review presents the classes of γ-secretase and beta-site APP cleaving enzyme 1 (BACE-1) inhibitors under development, highlighting their structure-activity relationship, among other physical-chemistry aspects important for the successful development of new anti-AD pharmacological agents. Full article
(This article belongs to the Special Issue Therapeutics Agents for Neural Repair)
Figures

Figure 1

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top